Brain health / cognition
Transcranial red light therapy for brain health and cognition
Emerging human evidence for transcranial photobiomodulation in cognition and mood, with clear separation from consumer panel claims.
Cited source set includes 10 records, including 7 source(s) imported from the PlatinumLED news source inventory.
low
not-panel-replicable
Bottom line
Brain-health claims need the most restraint: cite tPBM separately, avoid treating consumer panels as brain devices, and avoid mental-health treatment claims.
Consensus: tPBM has an intriguing positive signal for cognition, but the evidence is emerging, device-specific, and not equivalent to whole-body panels.
What the studies found
- A 2023 review identified 35 human studies and reported that 29 showed positive cognitive findings.
- A 2019 healthy-adult meta-analysis found improved cognition-related outcomes but noted possible publication bias.
- A depression-focused review described preliminary evidence and biological rationale, while calling for large RCTs.
- Platinum-sourced additions broaden the citation map; imported records need full-text review before converting them into stronger efficacy claims.
Dosage and timing
| Wavelengths | 630, 635, 810, 1060, 1068 nm |
|---|---|
| Irradiance | A common clinical-population protocol in one review used 20-25 mW/cm2. |
| Fluence | A common clinical-population protocol in one review used 1-10 J/cm2. |
| Session time | Varied by study. |
| Frequency | Varied by population and device. |
| Duration | Varied by population and device. |
| Timing | No general time-of-day consensus. |
| Treatment area | Scalp/transcranial targets. |
| Device types | Transcranial PBM helmets, arrays, or targeted devices. |
| Notes | Scalp penetration, placement, power, and safety screening are central. |
- The most common cited clinical-population protocol used 810 nm, 20-25 mW/cm2, and 1-10 J/cm2.
- There is no consensus that a consumer panel at a distance delivers a meaningful or safe transcranial dose.
- Mental-health and neurological uses should be described as experimental unless tied to clinician-supervised protocols.
- Imported records with missing protocol fields are not used as calculator presets.
Caveats
- Avoid claims that red light panels treat depression, dementia, traumatic brain injury, or neurological disease.
- Eye safety, heat, scalp dosing, and contraindications need more explicit review before any practical guide.
- Publication bias and trial quality are live concerns.
- Some added citations are indirect, mechanistic, animal, or specialist-device studies and should not be generalized to home panels.
Cited peer-reviewed sources
Lee TL, Ding Z, Chan AS. Ageing Research Reviews. 2023.
A systematic review found many positive cognitive studies, but only about half of clinical trials were randomized and sham-controlled.
Salehpour F, Majdi A, Pazhuhi M, et al. Photobiomodulation, Photomedicine, and Laser Surgery. 2019.
A meta-analysis of healthy adults reported improved cognition-related outcomes, but with publication-bias concerns.
systematic-review
Transcranial photobiomodulation for major depressive disorder review
Cassano P, Petrie SR, Hamblin MR, et al. Neurophotonics. 2016.
A review described preliminary evidence and biological rationale for tPBM in depression, while emphasizing the need for large RCTs.
animal-or-in-vitro
Potential for transcranial laser or LED therapy to treat stroke, traumatic brain injury, and neurodegenerative disease.
Naeser MA, Hamblin MR. Photomed Laser Surg. 2011.
Imported from the PlatinumLED news source inventory as a peer-reviewed citation. This first-pass record preserves source metadata and needs full-text protocol extraction before it should be used for consumer dosing guidance.
Nizamutdinov D, Qi X, Berman MH, Dougal G, Dayawansa S, Wu E, Yi SS, Stevens AB, Huang JH. Aging Dis. 2021.
Imported from the PlatinumLED news source inventory as a peer-reviewed citation. This first-pass record preserves source metadata and needs full-text protocol extraction before it should be used for consumer dosing guidance.
Hamblin MR. J Neurosci Res. 2018.
Imported from the PlatinumLED news source inventory as a peer-reviewed citation. This first-pass record preserves source metadata and needs full-text protocol extraction before it should be used for consumer dosing guidance.
Naeser MA, Zafonte R, Krengel MH, Martin PI, Frazier J, Hamblin MR, Knight JA, Meehan WP, Baker EH. J Neurotrauma. 2014.
Imported from the PlatinumLED news source inventory as a peer-reviewed citation. This first-pass record preserves source metadata and needs full-text protocol extraction before it should be used for consumer dosing guidance.
systematic-review
Transcranial and systemic photobiomodulation for major depressive disorder: A systematic review of efficacy, tolerability and biological mechanisms.
Caldieraro MA, Cassano P. J Affect Disord. 2019.
Imported from the PlatinumLED news source inventory as a peer-reviewed citation. This first-pass record preserves source metadata and needs full-text protocol extraction before it should be used for consumer dosing guidance.
randomized-controlled-trial
Acute effects of photobiomodulation therapy and magnetic field on functional mobility in stroke survivors: a randomized, sham-controlled, triple-blind, crossover, clinical trial.
Casalechi HL, Dumont AJL, Ferreira LAB, de Paiva PRV, Machado CDSM, de Carvalho PTC, Oliveira CS, Leal-Junior ECP. Lasers Med Sci. 2020.
Imported from the PlatinumLED news source inventory as a peer-reviewed citation. This first-pass record preserves source metadata and needs full-text protocol extraction before it should be used for consumer dosing guidance.
Schiffer F, Johnston AL, Ravichandran C, Polcari A, Teicher MH, Webb RH, Hamblin MR. Behav Brain Funct. 2009.
Imported from the PlatinumLED news source inventory as a peer-reviewed citation. This first-pass record preserves source metadata and needs full-text protocol extraction before it should be used for consumer dosing guidance.
Last reviewed: 2026-06-15